Dr. Earle Burgess on appropriate patients for PARP inhibitors in mCRPC

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, explains which patients with metastatic castration-resistant prostate cancer (mCRPC) are optimal for treatment with PARP inhibitors. The PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) are approved by the FDA for the treatment of patients with mCRPC.